Susquehanna International Group’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-14,993
| Closed | -$16K | – | 11351 |
|
|
2019
Q1 | $16K | Buy |
+14,993
| New | +$12.2K | ﹤0.01% | 8621 |
|
|
2018
Q4 | – | Sell |
-51,747
| Closed | -$110K | – | 10772 |
|
|
2018
Q3 | $110K | Buy |
51,747
+37,608
| +266% | +$90.1K | ﹤0.01% | 8570 |
|
|
2018
Q2 | $33K | Sell |
14,139
-74,610
| -84% | -$217K | ﹤0.01% | 9358 |
|
|
2018
Q1 | $282K | Buy |
+88,749
| New | +$245K | ﹤0.01% | 7736 |
|
|
2017
Q3 | – | Sell |
-53,124
| Closed | -$177K | – | 10346 |
|
|
2017
Q2 | $177K | Sell |
53,124
-6,678
| -11% | -$27.7K | ﹤0.01% | 8382 |
|
|
2017
Q1 | $551K | Sell |
59,802
-14,356
| -19% | -$126K | ﹤0.01% | 6310 |
|
|
2016
Q4 | $572K | Buy |
+74,158
| New | +$681K | ﹤0.01% | 6705 |
|
|
2016
Q1 | – | Sell |
-35,757
| Closed | -$420K | – | 10448 |
|
|
2015
Q4 | $806K | Buy |
35,757
+6,375
| +22% | +$131K | ﹤0.01% | 5851 |
|
|
2015
Q3 | $487K | Buy |
29,382
+12,197
| +71% | +$245K | ﹤0.01% | 7177 |
|
|
2015
Q2 | $387K | Sell |
17,185
-14,219
| -45% | -$351K | ﹤0.01% | 8096 |
|
|
2015
Q1 | $810K | Buy |
31,404
+12,736
| +68% | +$323K | ﹤0.01% | 6175 |
|
|
2014
Q4 | $406K | Buy |
+18,668
| New | +$382K | ﹤0.01% | 7621 |
|
Susquehanna International Group's OMED Position: Q2 2019 in Review
Susquehanna International Group sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2019, closing a stake of 14,993 shares — an estimated $16K sold.
Susquehanna International Group first reported a position in OMED in Q4 2014 and held it in 12 quarters. The position peaked at $810K in Q1 2015. 0 funds tracked by Wall St. Rank hold OMED as of Q2 2019.
- Susquehanna International Group reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
- Susquehanna International Group sold 14,993 OncoMed Pharmaceuticals, Inc. shares in Q2 2019, an estimated $16K.
- Susquehanna International Group first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2014 and held it in 12 quarters.
- Susquehanna International Group's OncoMed Pharmaceuticals, Inc. position peaked at $810K in Q1 2015.
- 0 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2019.
Based on Susquehanna International Group's 13F filing for Q2 2019, filed 14 Aug 2019.